- Bahreini A., Fathi R. 2017. Comparing the Effect of Eight Weeks of Interval and Continuous Aerobic Training on Serum Levels of WISP1 and TNF-α in Overweight/0bese Girls. Journal of Sport and Biomotor Sciences, 10(18):1-12.
- Brandt C., Pedersen B.K. 2010. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. BioMed Research International, 2010:520258.
- Bugger H., Abel E.D. 2009. Rodent models of diabetic cardiomyopathy. Disease Models and Mechanisms, 2(9-10):454-66.
- Chang J.S., Kim T.H., Kong I.D. 2020. Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: A randomized controlled trial. Scientific Reports, 10(1):1-9.
- Grünberg J.R., Hammarstedt A., Hedjazifar S., Smith U. 2014. The Novel Secreted Adipokine WNT1-Inducible-Signaling Pathway Protein2/WISP2 is a Mesenchymal Cell Activator of Canonical NT. Journal of Biological Chemistry. 2014:jbc.M113. 511964.
- Grünberg J. 2015. WISP-2-A Novel Adipokine Related to Obesity and Insulin resistance. University of Gothenburg Press.
- Grundy SM, Cleeman JI, Daniels SR, Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C. Jr, Spertus J.A., Costa F. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112(17):2735-2752.
- Gustafson B., Hammarstedt A., Hedjazifar S., Smith U. 2013. Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4. Diabetes, 62(9):2997-3004.
- Hammarstedt A., Hedjazifar S., Jenndahl L., Gogg S., Grünberg J., Gustafson B., et al. 2013. WISP2 regulates preadipocyte commitment and PPARγ activation by BMP4. Proceedings of the National Academy of Sciences, 110(7):2563-2568.
- Hörbelt T., Tacke C., Markova M., de Wiza D.H., Van de Velde F., Bekaert M., et al. 2018. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia, 61(9):2054-65.
- Klimontov V.V., Bulumbaeva D.M., Fazullina O.N., Lykov A.P., Bgatova N.P., Orlov N.B., Konenkov V.I., Pfeiffer A.F.H., Pivovarova-Ramich O., Rudovich N. 2020. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. Journal of Cell Communication and Signaling, 14(1):101-109.
- Kyu H.H., Bachman V.F., Alexander L.T., Mumford J.E., Afshin A., Estep K., Veerman J.L., Delwiche K., Iannarone M.L., Moyer M.L., Cercy K., Vos T., Murray C.J., Forouzanfar M.H. 2016. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ, 354:i3857.
- Maiese K., Chong Z.Z., Shang Y.C., Wang S. 2012. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opinion on Therapeutic Targets, 16(12):1203-1214.
- Maury E., Brichard S. 2010. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and Cellular Endocrinology, 314(1):1-16.
- Mirr M., Owecki M. 2021. An Update to the WISP-1/CCN4 role in obesity, insulin resistance and diabetes. Medicina, 57(2):100.
- Murahovschi V., Pivovarova O., Ilkavets I., Dmitrieva R.M., Döcke S, Keyhani-Nejad F., Gögebakan Ö., Osterhoff M., Kemper M., Hornemann S., Markova M., Klöting N., Stockmann M., Weickert M.O., Lamounier-Zepter V., Neuhaus P., Konradi A., Dooley S., von Loeffelholz C., Blüher M., Pfeiffer A.F., Rudovich N. 2014. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes, 2014:DB-140444.
- Murahovschi V., Pivovarova O., Ilkavets I., Dmitrieva R.M., Döcke S, Keyhani-Nejad F., Gögebakan Ö., Osterhoff M., Kemper M., Hornemann S., Markova M., Klöting N., Stockmann M., Weickert M.O., Lamounier-Zepter V., Neuhaus P., Konradi A., Dooley S., von Loeffelholz C., Blüher M., Pfeiffer A.F., Rudovich N. 2015. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes, 64(3):856-66.
- Pakradouni J., Le Goff W., Calmel C., Antoine B., Villard E., Frisdal E., Abifadel M., Tordjman J., Poitou C., Bonnefont-Rousselot D., Bittar R., Bruckert E., Clément K., Fève B., Martinerie C., Guérin M. 2013. Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders. PLoS One, 8(6):e66788.
- Peake J.M., Suzuki K., Coombes J.S. 2007. The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise. The Journal of Nutritional Biochemistry, 18(6):357-371.
- Roberts I., Kwan I., Evans P., Haig S. 2002. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. British Medical Journal, 324(7335):474.
- Tacke C., Aleksandrova K., Rehfeldt M., Murahovschi V., Markova M., Kemper M., Hornemann S., Kaiser U., Honig C., Gerbracht C., Kabisch S., Hörbelt T., Ouwens D.M., Weickert M.O., Boeing H., Pfeiffer A.F.H., Pivovarova O., Rudovich N. 2018. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. Journal of Cell Communication and Signaling,12(3):539-548.
- Talebi-Garakani E., Safarzade A. 2013. Resistance training decreases serum inflammatory markers in diabetic rats. Endocrine, 43(3):564-70.
|
